Related Experiment Video
Updated: Mar 26, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Is Long-Term Low-Dose Aspirin Therapy Associated with Renal Dysfunction in Patients with Type 2 Diabetes? JPAD2
Sadanori Okada1,2, Takeshi Morimoto3, Hisao Ogawa4
1Department of Diabetology, Nara Medical University, Kashihara, Nara, Japan.
Insights
Long-term low-dose aspirin use in type 2 diabetes patients does not harm kidney function. The study found no increased risk of renal dysfunction or changes in estimated glomerular filtration rate (eGFR) with aspirin treatment.
Area of Science:
- Nephrology
- Cardiology
- Endocrinology
Background:
- Cardiovascular disease (CVD) risk is high in diabetes patients.
- Low-dose aspirin is recommended for CVD prevention, but its long-term renal effects in diabetes are unclear.
Purpose of the Study:
- To investigate the long-term impact of low-dose aspirin on renal function in patients with type 2 diabetes.
Main Methods:
- A randomized controlled trial (RCT), the JPAD trial, followed by a cohort study.
- Patients with type 2 diabetes received either low-dose aspirin or no aspirin.
- Evaluated incidence of positive urine dipstick albumin and annual changes in estimated glomerular filtration rate (eGFR).
Main Results:
- Low-dose aspirin did not increase the incidence of positive urine dipstick albumin in intention-to-treat or on-treatment analyses.
- No significant differences in annual eGFR changes were observed between aspirin and no-aspirin groups.
- Factors like age, serum creatinine, HbA1c, and blood pressure influenced albuminuria risk, but not aspirin use.
Conclusions:
- Long-term low-dose aspirin use is safe for renal function in type 2 diabetes patients.
- Aspirin does not adversely affect eGFR or increase albuminuria in this population.
Background:
Low-dose aspirin is widely recommended for patients at high risk for cardiovascular disease (CVD); however, it remains uncertain whether long-term treatment adversely affects renal function in patients with diabetes. We investigated whether long-term low-dose aspirin affects renal dysfunction in patients with diabetes.
Methods:
We conducted a randomized controlled trial (RCT), the Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) trial, to evaluate low-dose aspirin as primary prevention for CVD in patients with type 2 diabetes. We followed the patients with negative urine dipstick albumin of the JPAD trial in a cohort study after the RCT period was completed. Patients were randomly allocated to receive aspirin (81 mg or 100 mg daily, aspirin group) or no aspirin (no aspirin group). After the RCT, the treating physician decided whether to administer aspirin. We evaluated the incidence of positive urine dipstick albumin and annual changes in estimated glomerular filtration rate (eGFR).
Results:
Positive urine dipstick albumin developed in 297 patients in the aspirin group (n = 1,075) and 270 patients in the no aspirin group (n = 1,098) during follow-up (median, 8.5 years). Intention-to-treat analysis showed low-dose aspirin did not increase the incidence of positive urine dipstick albumin (hazard ratio [HR], 1.17; 95% confidence interval [CI], 0.995-1.38). On-treatment analysis yielded similar results (HR, 1.08; 95% CI, 0.92-1.28). Multivariable analysis showed the incidence of positive urine dipstick albumin was higher among the elderly and those with elevated serum creatinine, high hemoglobin A1c, or high blood pressure; however, low-dose aspirin did not increase the risk of positive urine dipstick albumin. There were no significant differences in annual changes in eGFR between the groups (aspirin, -0.8 ± 2.9; no aspirin, -0.9 ± 2.5 ml/min/1.73 m(2)/year).
Conclusion:
Long-term low-dose aspirin does not affect eGFR and positive urine dipstick albumin in patients with type 2 diabetes.
More Related Videos
Related Concept Videos
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Antihypertensive Drugs: Direct Renin Inhibitors
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Peripheral Artery Disease III: Interprofessional Care
Antihypertensive Drugs: Potassium-Sparing Diuretics

